Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis.
Bisphosphonates are effective inhibitors of osteoclast activity and bone resorption, and are standard treatments for osteoporosis, hypercalcemia of malignancy, and metabolic bone disease. Bisphosphonates have also been established to effectively reduce skeletal-related events due to malignancy metastatic to bone. Bisphosphonates are now being incorporated into breast cancer treatment regimens in order to combat osteoporosis caused by ovarian suppression, chemotherapy treatment, aromatase inhibitors and the postmenopausal state itself. A large body of evidence suggests that African-American women are at higher risk for osteoporosis-related morbidity than their Caucasian counterparts. In this review, we highlight recommendations toward screening for osteoporosis in high-risk populations. We summarize the mechanisms of action of bisphosphonates in the treatment of osteoporosis and then summarize national recommendations toward incorporating the use of bisphosphonates as support for the bone health of breast cancer patients, as well as patients at high risk for osteoporosis.
Morris
Gloria J
GJ
Kimmel Cancer Center, Thomas Jefferson University Hospital, 111 S. 11th St., Suite 4240, Gibbon Building, Philadelphia, PA 19107, USA. Gloria.Morris@jefferson.edu
Mitchell
Edith P
EP
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates